<DOC>
	<DOCNO>NCT02683525</DOCNO>
	<brief_summary>Primary Objective Evaluate efficacy sitagliptin reduce incidence grade II-IV acute Graft Versus-Host Disease ( GvHD ) day +100 post-transplant patient undergo allogeneic hematopoietic stem cell transplantation receive standard sirolimus tacrolimus GvHD prophylaxis . Secondary Objectives The follow descriptive secondary objective study : 1 . Describe tolerability potential toxicity sitagliptin . 2 . Describe cumulative incidence grade II-IV acute GvHD day +100 . 3 . Describe cumulative incidence grade III-IV acute GvHD . 4 . Describe engraftment kinetics absolute neutrophil count platelet . 5 . Describe incidence infection occur 100 day post-transplant . 6 . Describe non-relapse mortality ( NRM ) day +30 , +100 , 1 year post-transplant . 7 . Describe overall survival . 8 . Describe incidence chronic GvHD . 9 . Describe cumulative incidence relapse primary hematological malignancy .</brief_summary>
	<brief_title>Sitagliptin Prevention Acute Graft Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation</brief_title>
	<detailed_description>This open label phase II study patient undergo allogeneic hematopoietic stem cell transplantation receive standard sirolimus tacrolimus GvHD prophylaxis . Although myeloablative preparative regimen prescribe , anticipated patient receive total body irradiation ( TBI ) plus etoposide ( TBI/VP16 ) , high-dose thiotepa plus cyclophosphamide accord institutional standard . Regardless preparative regimen , patient receive follow regimen GvHD prophylaxis , include study drug sitagliptin : Day -3 : Tacrolimus initiate day -3 suggest start dose 0.01 mg/kg/day IV continuous infusion modify target serum level 5-10 ng/ml . Serum level monitor least twice weekly discharge , time outpatient clinic visit accord institutional practice . Tacrolimus may switch PO dose patient able tolerate oral intake satisfactorily . Note concurrent use agent itraconazole , voriconazole fluconazole ( dose &gt; 200 mg ) may inhibit metabolism tacrolimus , thus increase tacrolimus level . Initial dosing may decrease order account increase level relate use 'azole ' agent . In addition , recommend check tacrolimus level twice weekly agent initiate concurrently . Sirolimus start day -3 suggest load dose 1 mg PO , 0.5 mg/day PO single dose day -2 maintain target serum level 5-10 ng/ml . Serum level monitor twice weekly discharge , time outpatient clinic visit accord institutional practice . Initial dosing may decrease order account increase level relate use 'azole ' agent . Day -1 : Sitagliptin 600 mg q 12 hour PO start Day -1 administer 8:00 10:00 give every 12 hour ( total 32 dos ) day +14 . In absence acute GvHD , begin taper tacrolimus sirolimus Day +100 tolerate goal stop Day +180 . The rate taper may adjust presence sign symptom GvHD . Mycophenolate mofetil may substitute tacrolimus sirolimus toxicity relate drug arises ( e.g. , renal failure , hemolytic microangiopathy , allergic rash , etc . ) .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>INCLUSION CRITERIA : A . Patients follow hematologic malignancy : 1 . Acute myeloid leukemia ( AML ) follow : 1 . In first remission ( CR1 ) intermediate risk highrisk cytogenetic and/or molecular feature . 2 . Patients second subsequent complete remission ( CR2 , CR3 , etc. ) . 3 . Primary refractory relapse AML one follow adverse additional feature accord modify CIBMTR criteria:49 Duration first CR &lt; 6 month Poor risk cytogenetics molecular feature ( FLT3 internal tandem duplication ( ITD ) ; complex karyotype ≥3 clonal abnormality , 5q/5 , 7q/7 , 11q23 abnormality , inv ( 3 ) , monosomal karyotype ) Circulating peripheral blood blast time enrollment Karnofsky performance status &lt; 90 % 2 . Acute lymphoblastic leukemia ( ALL ) follow : 1 . In CR1 subsequent complete remission ( CR2 , CR3 , etc . ) 2 . Primary refractory relapse ALL one follow adverse feature accord modify CIBMTR criteria:49 Second subsequent relapse Bone marrow blast &gt; 25 % time enrollment Age &gt; 40 year 3 . Myelodysplasia follow feature : 1 . Refractory anemia excess blast type I ( 510 % blast ) II ( 1120 % blast ) bone marrow ( RAEB I II ) 2 . Refractory cytopenia multilineage dysplasia ( RCMD ) poor risk cytogenetics ( i.e. , chromosome 7 abnormality complex karyotype least 3 abnormality per clone ) 4 . Chronic myelogenous leukemia ( CML ) one follow criterion : 1 . Accelerated phase , define follow : Blasts 1019 % peripheral blood white cell bone marrow Peripheral blood basophil least 20 % Persistent thrombocytopenia ( &lt; 100 x 109/l ) unrelated therapy , persistent thrombocytosis ( &gt; 1000 x 109/l ) unresponsive therapy Increasing spleen size increase white blood cell ( WBC ) count unresponsive therapy Cytogenetic evidence clonal evolution ( i.e. , appearance additional genetic abnormality present initial specimen time diagnosis chronic phase ) 2 . Chronic phase provide complete hematologic remission achieve 3 month complete cytogenetic remission 18 month patient receive least 2 tyrosine kinase inhibitor 5 . Patients aggressive nonHodgkin 's lymphoma ( NHL ) , include diffuse large cell lymphoma , mediastinal Bcell lymphoma , transform lymphoma , mantle cell lymphoma , peripheral T cell lymphoma , also one follow criterion : 1 . Failure achieve complete remission primary induction therapy 2 . Relapsed refractory least one line salvage systemic therapy 3 . Failed stem cell collection 6 . Patients Hodgkin 's lymphoma meeting one follow criterion : 1 . Primary refractory ( failure achieve complete remission primary induction therapy ) 2 . Relapsed refractory least one line salvage systemic therapy 3 . Failed stem cell collection B . Patient age ≥ 18 ≤ 60 year C. Karnofsky Performance status ≥ 70 % D. Patients must also receive full myeloablative preparative regimen ( Patients treat either total body irradiation ( TBI ) base highdose chemotherapy regimen eligible highdose busulfan contain regimen regimen include antithymocyte globulin T cell deplete antibody ) E. Patients receive allogeneic peripheral blood stem cell ( PBSC ) graft HLAmatched ( 5/6 6/6 match ) sibling well matched unrelated donor ( 9/10 10/10 match HLAA , B , C , DRB1 DQB1 high resolution type ) include . All graft unmanipulated ( i.e. , T cell deplete CD34 select graft ) . F. No uncontrolled bacterial , viral fungal infection time enrollment define currently take medication progression clinical symptom G. No HIV disease ( Patients immune dysfunction significantly high risk infection intensive immunosuppressive therapy ) H. Nonpregnant nonnursing I . Required baseline value within 60 day prior admission : 1 . LVEF ≥ 45 % 2 . DLCO ≥ 50 % predict ( correct hemoglobin ) J . Required baseline laboratory value within 16 day prior admission : 1 . Estimated creatinine clearance ≥60 ml/min 2 . Serum total bilirubin ≤ 2 x upper limit normal value ( ULN ) 3 . AST ALT ≤ 2 x ULN ( unless determine treat physician relate underlying malignancy ) K. Signed write informed consent ( Patient must capable understanding investigational nature , potential risk benefit study , able provide valid informed consent ) L. Patients must otherwise fulfill institutional criterion eligibility undergo myeloablative allogeneic stem cell transplantation EXCLUSION CRITERIA : A. Symptomatic uncontrolled coronary artery disease congestive heart failure B . Severe hypoxemia room air PaO2 &lt; 70 , supplemental oxygen dependence , DLCO &lt; 50 % predict C. Patients active central nervous system involvement D. Prior allogeneic autologous hematopoietic stem cell transplant past 12 month E. Patients diabetes mellitus require insulin secretagogues and/or insulin F. Patients hypertriglyceridemia serum triglyceride level ≥500 mg/d ( lipid lower drug may use control level ) G. Patients history pancreatitis H. Patients symptomatic cholelithiasis I . Patients current dependence alcohol ( characterized physical addiction alcohol interfere physical mental health , social , family job responsibility )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Allogeneic</keyword>
	<keyword>Sitagliptin</keyword>
</DOC>